Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced that Stuart M. Essig, chairman of Integra’s Board of Directors, has been appointed president and chief executive officer, effective May 1, 2026. Essig will continue to serve as chairman. He succeeds Mojdeh Poul, who is pursuing other opportunities.

The Company also announced that Michael McBreen, currently executive vice president and president of Codman Speciality Surgical, has been appointed chief commercial officer.

Essig brings more than thirty years of experience in the medical technology and healthcare industries and has deep familiarity with Integra, having served as chairman of the board since June 2012 and as a director since 1997. He previously served as Integra’s chief executive officer from 1997 through early 2012, and as its President from 1997 until 2010. Over the past two years, Essig has been actively engaged in the business through his executive chairman role, with direct involvement in key company priorities as well as operational and quality matters.

"Stuart brings unmatched knowledge of Integra, its businesses, and its people," said Barbara Hill, presiding director. "He combines deep institutional knowledge with a clear understanding of the work underway across the organisation. We have full confidence in his leadership as Integra accelerates execution, strengthens customer and commercial focus, and builds on the important progress already underway across its priorities for 2026. The Board believes this is the right leadership step for the Company’s next phase, and as such, this is not an interim role, and we do not intend to initiate a CEO search."

"I am honoured to once again serve as Integra’s president and CEO," said Essig. "I return with a clear mandate from the Board and a long-term commitment to lead the Company through its next chapter. In my role as executive chairman, I have seen firsthand the strength of our team and the meaningful progress underway across our priorities, particularly in quality, compliance, operational resilience, and the transformation of the organisation.”

Essig continued, " As I step back into the CEO role, my focus will be on accelerating execution, strengthening our customer and commercial focus, and reinforcing a culture and operating discipline that will drive sustained performance and deliver long-term shareholder value. I know this company, I understand what it takes to run it, and I am deeply committed to leading Integra forward."

Essig added, "I also want to thank Mojdeh for her numerous contributions to the company and for the meaningful progress made during her tenure. Under her leadership, the Company advanced several important strategic and operational priorities, including enterprise-wide portfolio and program prioritisation, risk-based approach to quality remediation work, operational resiliency improvements, and the more recent transformation and business process optimisation efforts. These initiatives are progressing well, and we remain fully committed to them.”